SCHEMBL6705646

SCHEMBL6705646

CCCCCCCCCCCCCCCCCCc1ccc(C(c2ccccc2)c2ccc(CCCCCCCCCCCCCCCCCC)cc2O)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 1/20 0.56
PPARA Q07869 1/20 0.51
IGF1R P08069 1/20 0.49
ALOX15 P16050 1/20 0.49
KAT8 Q9H7Z6 2/20 0.48
ESR1 P03372 2/20 0.47
ADRA2A P08913 2/20 0.47
ADORA3 P0DMS8 2/20 0.47
TACR2 P21452 2/20 0.47
SLC6A2 P23975 2/20 0.47
SLC6A4 P31645 2/20 0.47
SLC6A3 Q01959 2/20 0.47
KDM4E B2RXH2 1/20 0.47
ALDH1A1 P00352 1/20 0.47
LMNA P02545 1/20 0.47
SHBG P04278 1/20 0.47
TP53 P04637 1/20 0.47
CYP3A4 P08684 1/20 0.47
HSPD1 P10809 1/20 0.47
ADRB3 P13945 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL382808 0.82 HTR2A (0.73) HTR2AESR1ADRA2AADORA3TACR2
SCHEMBL27919484 0.80 IGF1R (0.46) HTR2APPARAIGF1RALOX15KAT8
SCHEMBL11002546 0.78 IGF1R (0.80) PPARAIGF1RALOX15KAT8ESR1
SCHEMBL31545797 0.78 PPARA (0.56) PPARAKAT8ESR1ADRA2AADORA3
SCHEMBL19806870 0.77 TYR (0.50) ALOX15ESR1ADRA2AADORA3TACR2
SCHEMBL11881888 0.77 KAT8 (0.52) HTR2APPARAIGF1RALOX15KAT8
SCHEMBL3111015 0.77 KAT8 (0.52) HTR2APPARAIGF1RALOX15KAT8
SCHEMBL11602738 0.76 HTR2A (0.69) HTR2AESR1ADRA2AADORA3TACR2
SCHEMBL6284501 0.76 HTR2A (0.69) HTR2AESR1ADRA2AADORA3TACR2
SCHEMBL50781 0.76 TRPA1 (0.50) IGF1RALOX15KDM4EALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040116685-A1 Method for solution phase synthesis of oligonucleotides PROLIGO LLC 2004-06-17 US disclosed
EP-0996627-A4 METHOD FOR SOLUTION PHASE SYNTHESIS OF OLIGONUCLEOTIDES AND PEPTIDES PROLIGO L L C (US) 2002-01-02 EP disclosed
US-6262251-B1 PRODUCT ANCHORED SEQUENCIAL SYNTHESIS (PASS); AN ANCHOR GROUP ATTACHED TO THE 5' END OF THE GROWING OLIGONUCLEOTIDE PRODUCT ALLOWS THE COUPLED PRODUCT TO BE SEPARATED FROM UNREACTED STARTING MATERIALS PROLIGO LLC 2001-07-17 US disclosed
EP-0979233-A4 METHOD FOR SOLUTION PHASE SYNTHESIS OF OLIGONUCLEOTIDES PROLIGO L L C (US) 2001-03-21 EP disclosed
EP-0996627-A1 METHOD FOR SOLUTION PHASE SYNTHESIS OF OLIGONUCLEOTIDES AND PEPTIDES Proligo L.L.C. (US) 2000-05-03 EP disclosed
EP-0979233-A1 METHOD FOR SOLUTION PHASE SYNTHESIS OF OLIGONUCLEOTIDES NeXstar Pharmaceuticals, Inc. (US) 2000-02-16 EP disclosed
US-6001966-A REACTING N-TERMINAL PROTECTED AMINO ACID WITH PEPTIDE STARTING MATERIAL FORMING A PEPTIDE PRODUCT, PARTITIONING FROM UNREACTED MATERIAL AND REAGENTS BASED ON PRESENCE OF N-TERMINAL BLOCKING/ANCHORING GROUP PROLIGO LLC (US) 1999-12-14 US disclosed
US-5874532-A USING A N-TERMINAL PROTECTED AMINO ACID MONOMER NEXSTAR PHARMACEUTICALS, INC. (US) 1999-02-23 US disclosed
WO-1998047910-A1 METHOD FOR SOLUTION PHASE SYNTHESIS OF OLIGONUCLEOTIDES PROLIGO LLC (US) 1998-10-29 WO disclosed
EP-0863910-A1 METHOD FOR SOLUTION PHASE SYNTHESIS OF OLIGONUCLEOTIDES NeXstar Pharmaceuticals, Inc. (US) 1998-09-16 EP disclosed
WO-1998030578-A1 METHOD FOR SOLUTION PHASE SYNTHESIS OF OLIGONUCLEOTIDES AND PEPTIDES PROLIGO LLC (US) 1998-07-16 WO disclosed
WO-1997014706-A1 METHOD FOR SOLUTION PHASE SYNTHESIS OF OLIGONUCLEOTIDES NEXSTAR PHARMACEUTICALS, INC. (US) 1997-04-24 WO disclosed